TRAX First Tracks Biotherapeutics Inc

QT88

Latest market price

45.80

+0.74+1.65%

Overview Short InterestFilings

TRAXQT88First Tracks Biotherapeutics Inc·NASDAQ

Overview Short InterestFilings

45.80+1.65%

Loading chart...

Signal & projected range

Short-squeeze setupHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

NUVB+2.29%$4.70 RARE+2.56%$16.72 NTLA+4.63%$12.20 QURE+2.00%$23.43 KLRA+4.36%$12.68 ABSI+5.78%$10.25 URGN-0.82%$34.08 MAZE+2.22%$31.05

Snapshot

Index	—	P/E	—	EPS (ttm)	—	Insider Own	2.20%	Shs Outstand	35.91M	Perf Week	3.61%

Market Cap	1.62B	Forward P/E	—	EPS next Y	-3.68	Insider Trans	-4.98%	Shs Float	30.64M	Perf Month	35.37%

Enterprise Value	1.45B	PEG	—	EPS next Q	-0.92			Short Float	22.71%	Perf Quarter	-2.09%

Income	-166.00M	P/S	—	EPS this Y	—			Short Ratio	8.22	Perf Half Y	119.22%

Sales	0.00	P/B	9.57	EPS next Y	—	ROA	-68.97%	Short Interest	6.96M	Perf YTD	119.65%

Book/sh	4.71	P/C	9.63	EPS next 5Y	—	ROE	-53.09%	52W High	49.91 -8.24%	Perf Year	—

Cash/sh	4.68	P/FCF	—	EPS past 3/5Y	—	ROIC	-77.19%	52W Low	14.72 211.11%	Perf 3Y	—

Dividend Est.	—	EV/EBITDA	—	Sales past 3/5Y	—	Gross Margin	0.00%	Volatility	6.01% 8.61%	Perf 5Y	—

Dividend TTM	—	EV/Sales	—	EPS Y/Y TTM	—	Oper. Margin	0.00%	ATR (14)	3.10	Perf 10Y	—

Dividend Ex-Date	—	Quick Ratio	14.28	Sales Y/Y TTM	—	Profit Margin	0.00%	RSI (14)	65.67	Recom	2.00

Dividend Gr. 3/5Y	—	Current Ratio	14.28	EPS Q/Q	34.48%	SMA20	16.46%	Beta	2.27	Target Price	71.33

Payout	0.00%	Debt/Eq	0.02	Sales Q/Q	—	SMA50	15.64%	Rel Volume	0.51	Prev Close	45.05

Employees	104	LT Debt/Eq	0.01	Earnings	Nov 11	SMA200	44.50%	Avg Volume	832.14K	Price	45.80

IPO Date	Apr 20, 2026	Option/Short	No / Yes	EPS/Sales Surpr.	-18.37% —	Net Debt/EBITDA	—	Volume	426,382	Change	1.65%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Oct-13-26	Reiterated	Evercore ISI Group	Outperform	$65 → $70
Oct-13-26	Reiterated	Canaccord Genuity	Buy	$50 → $60
Oct-09-26	Reiterated	Wells Fargo	Overweight	$55 → $62
Sep-30-26	Initiated	Canaccord	Buy	$50
Sep-18-26	Initiated	Evercore ISI	Outperform	$65
Sep-16-26	Initiated	Guggenheim	Buy	$100
Aug-13-26	Reiterated	Piper Sandler	Overweight	$54 → $95
Aug-13-26	Reiterated	HC Wainwright & Co.	Buy	$44 → $57
Aug-13-26	Reiterated	Barclays	Overweight	$48 → $65
Aug-10-26	Reiterated	UBS	Buy	$45 → $65

Latest News· Times ET

Oct-16-26

Oct-16-2604:36AM

Leerink Partners Maintains Outperform on First Tracks, Raises Price Target to $90Benzinga

Oct-15-26

Oct-15-2608:00AM

First Tracks Biotherapeutics Announces $200 Million Private Placementglobenewswire.com

Oct-14-26

Oct-14-2608:15AM

First Tracks Biotherapeutics: Teva Validated The Pathway, ANB033 May Own The Receptorseekingalpha.com

Oct-13-26

Oct-13-2605:03AM

First Tracks’ ANB033 Clears Key Phase Ib Celiac Disease Study Goalsdefenseworld.net

Oct-12-26

Oct-12-2605:26PM

First Tracks climbs on ‘impressive’ celiac study dataYahoo

01:03PM

First Tracks' ANB033 Clears Key Phase Ib Celiac Disease Study Goalsmarketbeat.com

09:55AM

First Tracks Biotherapeutics, C3.ai, CCC Intelligent Solutions And Other Big Stocks Moving Higher On Mondaybenzinga.com

Oct-11-26

Oct-11-2604:00PM

First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026globenewswire.com

Sep-30-26

Sep-30-2603:36AM

Canaccord Genuity Initiates Coverage On First Tracks with Buy Rating, Announces Price Target of $50Benzinga

Sep-25-26

Sep-25-2611:38PM

AnaptysBio (ANAB) Reports a Tax-Driven Profit. When Will Royalties Fund Shareholder Returns?Yahoo

Sep-18-26

Sep-18-2603:53AM

This Cue Biopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For FridayBenzinga

Sep-16-26

Sep-16-2604:12AM

Guggenheim Initiates Coverage On First Tracks with Buy Rating, Announces Price Target of $100Benzinga

Sep-10-26

Sep-10-2608:52AM

Rosnilimab Emerges as a Potential Advance in Rheumatoid Arthritis as Physicians Look to the Next Wave of Pipeline InnovationYahoo

Sep-07-26

Sep-07-2604:41AM

Insider Selling: First Tracks Biotherapeutics (NASDAQ:TRAX) Director Sells $1,758,286.70 in Stockdefenseworld.net

Sep-02-26

Sep-02-2610:30AM

Which stocks are gapping on Wednesday?ChartMill

Company

First Tracks Biotherapeutics, Inc., situated in San Diego, California, specializes in pioneering new immunology-based treatments. The firm is actively involved in the discovery and progression of therapeutics aimed at combating autoimmune and inflammatory disorders, currently advancing programs like rosnilimab, ANB033, and ANB101 through their clinical stages.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023
Total Revenue	0	0	0
Cost of Goods Sold Incl. D&A	140	152	0
Gross Profit	-140	-152	0
Selling, General and Administrative Excl. Other	39	29	21
Research and Development	140	152	98
Other Operating Expense	-140	-152	-1
Operating Income	-179	-181	-118
Interest Expense	0	0	0
Unusual Expense	—	—	—
Non-Operating Income (Expense)	13	17	12
Net Income Before Taxes	-166	-164	-106
Income Taxes	0	0	0
Consolidated Net Income	-166	-164	-106
Net Income From Continuing Operations	-166	-164	-106
Net Income	-166	-164	-106
EPS (Recurring)	0.00	0.00	-3.05
EPS (Basic, Before Extraordinaries)	0.00	0.00	-3.05
EPS (Diluted)	0.00	0.00	-3.05
EBITDA	-177	-179	-116
Other After Tax Adjustments	—	—	—
Stock Option Compensation Expense	—	—	—
Price To Earnings Ratio	—	—	—
Price To Sales Ratio	—	—	—
Gross Margin	—	—	—
Operating Margin	—	—	—
Net Margin	—	—	—
Shares Outstanding	35	35	35
Market Capitalization	—	—	—
Operating Lease Expense	—	—	—

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Orwin John A	Director	Sep 15 '26	Option Exercise	0.00	1,300	0	17,995	Sep 17
Ware J. Anthony	Director	Sep 02 '26	Option Exercise	5.74	78,530	450,763	54,925	Sep 04
Ware J. Anthony	Director	Sep 02 '26	Sale	44.78	39,265	1,758,145	15,660	Sep 04

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.